DOCSLIB.ORG

Intermediates Products Name of Goods CAS No

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Intermediates Products Name of Goods CAS No تامین کننده : مواد اولیه تولید دارو ، واکسن ، سرم ، مواد اولیه تولید محصوﻻت آرایشی ، انواع عصاره های گیاهی و لوازم بسته بندی دارویی تهران ، خیابان خالد اسﻻمبولی )وزرا( کوچه 61 پﻻک 8 واحد 2 تلفن : [email protected] 09125117502 / 02188718355 Intermediates Products Name of Goods CAS No. 1、2,5-Diamino-4,6-Dihydroxy Pyrimidine Hcl Monohydrate 56830-58-1 2、4,6-Dichloro Pyrimidine-2,5-Diamine 55583-59-0 3、N-(2-Amino-4,6-Dichloropyrimidine-5-Yl)Formamide 171887-03-9 Abaperidone Intermediates 1、2-[2-Hydroxy-4-(3-Chloro Propyloxy)Phenyl]Ethanone 2、8-(3-Chloro Propyloxy)-4-Oxo-4H-1-Benzopyran-3-Methanol 3、N-Acetyl Piperdine-4-Carboxylic Acid 25503-90-6 4、N-Acetyl-4-Piperidine Carbonyl Chloride Aceclofenac Intermediates 1-(2,6-Dichlorophenyl)Indane-2-One 15362-40-0 Acetazolamide Intermediates Acetamide N-[5-(Amino Sulphony)-1,3,4 Thiadiazol-2-Yl] Acetophenazine Intermediates 1-(3-Chloropropyl)-4-(2-Hydroxyethyl)Piperazine Dihcl Acetoprol/Ethiprole Intermediates 4-Tolyl Isocyanate 622-58-2 Acrivastine Intermediates N-(2-Chloroethyl)Pyrrolidine 5050-41-9 Actarit Intermediates 4-Amino Phenyl Acetic Acid 1197-55-3 محصوﻻت پیشنهادی ما مطابق با فارماکوپه های مختلف بین المللی با استاندارد EP, USP, BP, JP, IP یا CP و سایر ویژگیهای موردنیاز میباشد ، تمام API های ما ، مورد تایید GMP یا cGMP هستند و بسیاری از آنها توسط DMF, FDA, CEP و Halal تایید و حمایت می شوند. تامین کننده : مواد اولیه تولید دارو ، واکسن ، سرم ، مواد اولیه تولید محصوﻻت آرایشی ، انواع عصاره های گیاهی و لوازم بسته بندی دارویی تهران ، خیابان خالد اسﻻمبولی )وزرا( کوچه 61 پﻻک 8 واحد 2 تلفن : [email protected] 09125117502 / 02188718355 Adapalene Intermediates 1、2-(1-Adamantyl)-4-Bromo Phenol 104224-68-2 2、2-(1-Adamantyl)-4-Bromo Anisole 104224-63-7 3、4-Bromo-2-(Tricyclo[3,3,1,1(3,7)]Dec-1-Yl)Phenol 4、Dibromo Triphenyl Phospine 1034-39-5 Adapalene/Thiamphenicol Intermediates 4-Bromo Benzaldehyde 1122-91-4 Albendazole/Itraconazole Intermediates 4-Chloro Nitrobenzene 100-00-5 Albuterol Sulfate Intermediates 1、1-(4-Benzyloxy-3-Hydroxyl Methylphenyl)-2-(Tertiarybutylamino)Ethanol 2、1-[(3-Carboxymethyl)-4`-Benzyloxy]-2-N-Tertiary Butylamino Acetophenone Alendronate Sodium Intermediates 1、4-Amino-1-Hydroxybutylidene)Bisphosphonic Acid (Alendronic Acid ) 66376-36-1 2、4-Amino Butyric Acid 56-12-2 Alfaprostol Intermediates 3-Phenyl Propionaldehyde 104-53-0 Alfuzosin/Terazosin Intermediates Tetra-Hydro-2-Methyl Furoate 37443-42-8 Alfuzosin Intermediates 1、6,7-Dimethoxy-2,4-(1H,3h)-Quinazolinedione 28888-44-0 2、N-Methyl-N-(4-Amino-6,7-Dimethoxy-2-Quinazolinyl)-1,3-Propane Diamine محصوﻻت پیشنهادی ما مطابق با فارماکوپه های مختلف بین المللی با استاندارد EP, USP, BP, JP, IP یا CP و سایر ویژگیهای موردنیاز میباشد ، تمام API های ما ، مورد تایید GMP یا cGMP هستند و بسیاری از آنها توسط DMF, FDA, CEP و Halal تایید و حمایت می شوند. تامین کننده : مواد اولیه تولید دارو ، واکسن ، سرم ، مواد اولیه تولید محصوﻻت آرایشی ، انواع عصاره های گیاهی و لوازم بسته بندی دارویی تهران ، خیابان خالد اسﻻمبولی )وزرا( کوچه 61 پﻻک 8 واحد 2 تلفن : [email protected] 09125117502 / 02188718355 3、Tetra-Hydro-2-Furoic Acid 16874-33-2 4、Tetra-Hydro-Furan-2-Carboxylix Acid(3-Methyl Amino Propyl)Amide Alizapride Intermediates 1、2-Methoxy-4,5-Diamino Benzoic Acid 59338-85-1 2、2-Methoxy-4-Acetamido-5-Nitro Benzoic Acid Methyl Ester 4093-41-8 3、5-Carboxy-6-Methoxy-1,2,3-Benzotriazole Allethrolone/Pralnacasan Intermediates 5-Bromo Valeric Acid 2067-33-6 Allopurinol Intermediates 1、3-Amino Pyrazole-4-Carboxamide Hemisulfate 27511-79-1 2、3-Morpholino-2-Cyano Acrylamide 25229-97-4 Allopurinol/Nevirapine Intermediates 2-Cyano Acetamide 107-91-5 Alminoprofen/Actarit Intermediates 4-Nitro Phenyl Acetic Acid 104-03-0 Almotriptan Intermediates 1、[4-(1-Pyrrolidinylsulfonylmethyl)Phenylhydrazine 334981-11-2 2、4-(Pyrrolidino Sulfonyl Methyl)Benzeneamine 334981-10-1 3、4-Aminophenyl Piperidyl Methane Sulphonamide 4、4-Chlorobutanal Dimethylacetal 29882-07-3 5、N-[(4-Amino Phenyl)Methyl Sulfonyl]Pyrrolidine 334981-10-1 Alphaprodine Hcl Intermediates محصوﻻت پیشنهادی ما مطابق با فارماکوپه های مختلف بین المللی با استاندارد EP, USP, BP, JP, IP یا CP و سایر ویژگیهای موردنیاز میباشد ، تمام API های ما ، مورد تایید GMP یا cGMP هستند و بسیاری از آنها توسط DMF, FDA, CEP و Halal تایید و حمایت می شوند. تامین کننده : مواد اولیه تولید دارو ، واکسن ، سرم ، مواد اولیه تولید محصوﻻت آرایشی ، انواع عصاره های گیاهی و لوازم بسته بندی دارویی تهران ، خیابان خالد اسﻻمبولی )وزرا( کوچه 61 پﻻک 8 واحد 2 تلفن : [email protected] 09125117502 / 02188718355 1,3-Dimethyl-4-Piperdinone 4629-80-5 Alpidem Intermediates 4-Chlorophenacyl Bromide 536-38-9 Alprazolam Intermediates 1、7-Chloro-1,3-Dihydro-5-Phenyl-2H-1,4-Benzodiazepin-2-One 1088-11-5 2、7-Chloro-1,3-Dihydro-5-Phenyl-2H-1,4-Benzodiazepin-2-Thione 4547-02-8 3、Nordiazepam Thio Compound 4、P-Amino Benzophenone 1137-41-3 Alprazolam/Estemazolam Intermediates 2-Amino 5-Chloro Benzophenone 719-59-5 Ambroxol Intermediates 1、2-Amino-3,5-Dibromo Benzaldehyde 50910-55-9 2、Trans-4-Amino Cyclohexanol 27489-62-9 Amfobutamone Intermediates 3-Chloropropio Phenone 34841-35-5 Amicarbalide/Imidocarb Intermediates 3-Amino Benzonitrile 2237-30-1 Amifloxacin/Ciprofloxacin Intermediates 3-Chloro-4-Fluoroaniline 367-21-5 Amiloride Hcl Intermediates 1、Methyl-3-Aminopyrazine-2-Carboxylate 16298-03-6 2、Methyl-6-Chloro-3,5-Diamino Pyrazine-2-Carboxylate 1458-01-1 محصوﻻت پیشنهادی ما مطابق با فارماکوپه های مختلف بین المللی با استاندارد EP, USP, BP, JP, IP یا CP و سایر ویژگیهای موردنیاز میباشد ، تمام API های ما ، مورد تایید GMP یا cGMP هستند و بسیاری از آنها توسط DMF, FDA, CEP و Halal تایید و حمایت می شوند. تامین کننده : مواد اولیه تولید دارو ، واکسن ، سرم ، مواد اولیه تولید محصوﻻت آرایشی ، انواع عصاره های گیاهی و لوازم بسته بندی دارویی تهران ، خیابان خالد اسﻻمبولی )وزرا( کوچه 61 پﻻک 8 واحد 2 تلفن : [email protected] 09125117502 / 02188718355 3、4-Amino-2,6-Dihydroxy Pyrimidine 873-83-6 Amiloride Intermediates Ethyl Cyano Acetate 105-56-6 Amineptine Intermediates 1、7-Bromoheptanoic Acid 30515-28-7 2、7-Aminoheptanoic Acid 929-17-9 Aminoglutethimide/Butethamate/Fenbutrazate Intermediates 2-Phenoxyethylamine 1758-46-9 Amisulpride Intermediates 1-Ethylpyrrolidine-2-Carbonitrile 62842-34-6 2-Methoxy-4-Amino-5-Ethylsulfonyl Benzoic Acid(Methyl Ester) 71675-87-1 Amitriptyline Intermediates 1、Dibenzosuberone 1210-35-1 2、Dimethyl Amino Propl Chloride Hcl Eoplamine Intermediates N-(2-Hydroxyethyl)Pyrrolidine 2955-88-6 Chloropromazine Hcl Intermediates 2-Chloro Phenothiazine 92-39-7 Levetiracetam Intermediates Triethyl Phosphonoacetate 867-13-0 Amitriptyline/Chlorpromazine Intermediates محصوﻻت پیشنهادی ما مطابق با فارماکوپه های مختلف بین المللی با استاندارد EP, USP, BP, JP, IP یا CP و سایر ویژگیهای موردنیاز میباشد ، تمام API های ما ، مورد تایید GMP یا cGMP هستند و بسیاری از آنها توسط DMF, FDA, CEP و Halal تایید و حمایت می شوند. تامین کننده : مواد اولیه تولید دارو ، واکسن ، سرم ، مواد اولیه تولید محصوﻻت آرایشی ، انواع عصاره های گیاهی و لوازم بسته بندی دارویی تهران ، خیابان خالد اسﻻمبولی )وزرا( کوچه 61 پﻻک 8 واحد 2 تلفن : [email protected] 09125117502 / 02188718355 3-(Dimethyl Amino)Propyl Chloride Hcl 5407-04-5 Amlodipine Besylate Intermediates 1、2-[(2-Aminoethoxy)Methyl]-4-(2-Chlorophenyl)-3-Ethoxy Carbonyl-5-Methoxy 88150-42-9 Carbonyl-6-Methyl-1,4-Dihydropyridine 2、2-[(2-Phthaloylethoxy)Methyl]-4-(2-Chlorophenyl)-3-Ethoxy Carbonyl-5-Methoxy- Carbonyl-6-Methyl-1,4-Dihydropyridine 3、3-Aminocrotonic Acid Methyl Ester 14205-39-1 4、4-(2-Chlorophenyl)-3-Ethoxycarbonyl-5-Methoxycarbonyl-6-Methyl-2-[(2- Phthalimido Ethoxy)Methyl]-1,4-Dihydropyridine 5、Amlodipine Base 88150-47-4 6、Hydroxy Ethyl Phthalamide 7、Methyl-3-Amino Crotonate 14205-39-1 8、Phthalimido Ethanol 9、Phthaloyl Amlodipine 88150-62-3 Amlodipine Intermediates (2-Hydroxy Ethyl)Phthalimide 3891-07-4 Amosulalol/Carvedilol Intermediates 2-(2-Methoxyphenoxy)Ethylamine 1836-62-0 Amosulalol Intermediates 4-Methyl-3`-Nitro Acetophenone 5333-27-7 Amoxycillin/Cefadroxil Intermediates D(-)Phpg Dane Salt Amperozide Intermediates محصوﻻت پیشنهادی ما مطابق با فارماکوپه های مختلف بین المللی با استاندارد EP, USP, BP, JP, IP یا CP و سایر ویژگیهای موردنیاز میباشد ، تمام API های ما ، مورد تایید GMP یا cGMP هستند و بسیاری از آنها توسط DMF, FDA, CEP و Halal تایید و حمایت می شوند. تامین کننده : مواد اولیه تولید دارو ، واکسن ، سرم ، مواد اولیه تولید محصوﻻت آرایشی ، انواع عصاره های گیاهی و لوازم بسته بندی دارویی تهران ، خیابان خالد اسﻻمبولی )وزرا( کوچه 61 پﻻک 8 واحد 2 تلفن : [email protected] 09125117502 / 02188718355 4,4-Di(4-Fluorophenyl)-1-Chlorobutane Ampicillin/Amoxycillin Intermediates 2,6-Lutidine 108-48-5 Anagrelide Hcl Intermediates 1、Ethyl-5,6-Dichloro-3,4-Dihydro-2-[1H]Imino Quinazoline-3-Acetate 2、2,3,4-Trichloro Nitro Benzene 17700-09-3 Anagrelide Hcl/Pergolide Intermediates Cyanogen Bromide 506-68-3 Anastrazole Intermediates 1、5-Methyl-1,3-Benzene Diacetonitrile 120511-74-2 2、3,5-Bis(2-Cyanoisopropyl)Toluene 120511-72-0 Ancitabine Hcl/Cefmenoxim Intermediates Trityl Chloride 76-83-5 Anisindione/Venlafaxine Intermediates 4-Methoxy Phenylacetonitrile 104-47-2 Antipyrine/Aminopyrine/Ramiphenazone Intermediates 3-Methyl-1-Phenyl-2-Pyrazolin-5-One 89-25-8 Antrafenine Intermediates N-[(3-Trifluoromethyl)Phenyl]Piperazine Hcl 16015-69-3 Apomorphine Intermediates Vanillyl Alcohol 498-00-0 محصوﻻت پیشنهادی ما مطابق با فارماکوپه های مختلف بین المللی با استاندارد EP, USP, BP, JP, IP یا CP و سایر ویژگیهای موردنیاز میباشد ، تمام API های ما ، مورد تایید GMP یا cGMP هستند و بسیاری از آنها توسط DMF, FDA, CEP و Halal تایید و حمایت می شوند. تامین کننده : مواد اولیه تولید دارو ، واکسن ، سرم ، مواد اولیه تولید محصوﻻت آرایشی ، انواع
Load more

Recommended publications
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • WO 2015/072852 Al 21 May 2015 (21.05.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/072852 Al 21 May 2015 (21.05.2015) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 36/84 (2006.01) A61K 31/5513 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/045 (2006.01) A61P 31/22 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/522 (2006.01) A61K 45/06 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, PCT/NL20 14/050780 KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (22) International Filing Date: MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, 13 November 2014 (13.1 1.2014) PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (25) Filing Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 61/903,430 13 November 2013 (13. 11.2013) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: RJG DEVELOPMENTS B.V.
    [Show full text]
  • Pharmacology on Your Palms CLASSIFICATION of the DRUGS
    Pharmacology on your palms CLASSIFICATION OF THE DRUGS DRUGS FROM DRUGS AFFECTING THE ORGANS CHEMOTHERAPEUTIC DIFFERENT DRUGS AFFECTING THE NERVOUS SYSTEM AND TISSUES DRUGS PHARMACOLOGICAL GROUPS Drugs affecting peripheral Antitumor drugs Drugs affecting the cardiovascular Antimicrobial, antiviral, Drugs affecting the nervous system Antiallergic drugs system antiparasitic drugs central nervous system Drugs affecting the sensory Antidotes nerve endings Cardiac glycosides Antibiotics CNS DEPRESSANTS (AFFECTING THE Antihypertensive drugs Sulfonamides Analgesics (opioid, AFFERENT INNERVATION) Antianginal drugs Antituberculous drugs analgesics-antipyretics, Antiarrhythmic drugs Antihelminthic drugs NSAIDs) Local anaesthetics Antihyperlipidemic drugs Antifungal drugs Sedative and hypnotic Coating drugs Spasmolytics Antiviral drugs drugs Adsorbents Drugs affecting the excretory system Antimalarial drugs Tranquilizers Astringents Diuretics Antisyphilitic drugs Neuroleptics Expectorants Drugs affecting the hemopoietic system Antiseptics Anticonvulsants Irritant drugs Drugs affecting blood coagulation Disinfectants Antiparkinsonian drugs Drugs affecting peripheral Drugs affecting erythro- and leukopoiesis General anaesthetics neurotransmitter processes Drugs affecting the digestive system CNS STIMULANTS (AFFECTING THE Anorectic drugs Psychomotor stimulants EFFERENT PART OF THE Bitter stuffs. Drugs for replacement therapy Analeptics NERVOUS SYSTEM) Antiacid drugs Antidepressants Direct-acting-cholinomimetics Antiulcer drugs Nootropics (Cognitive
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2007/0142328A1 Chapdelaine Et Al
    US 2007 O142328A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2007/0142328A1 Chapdelaine et al. (43) Pub. Date: Jun. 21, 2007 (54) COMPOUNDS AND USES THEREOF Publication Classification (51) Int. Cl. (75) Inventors: Marc J. Chapdelaine, Wilmington, DE A6II 3/695 (2006.01) (US); Cyrus J. Ohnmacht, A6II 3 L/502 (2006.01) Wilmington, DE (US); Christopher C07F 7/02 (2006.01) Becker, West Chester, PA (US); C07D 237/28 (2006.01) Hui-Fang Chang, Wilmington, DE (52) U.S. Cl. ............................ 514/63; 514/248; 544/235; (US); Bruce T. Dembofsky, 544,229 Wallingford, PA (US) (57) ABSTRACT This invention relates to novel compounds having the struc Correspondence Address: tural formula I below: ASTRAZENECA PHARMACEUTICALS LP GLOBAL INTELLECTUAL PROPERTY 18OO CONCORD PIKE R3 yH O WILMINGTON, DE 19850-5437 (US) R RI N N1 H (73) Assignee: AstraZeneca AB, Sodertalje (SE) 2 N R5 2 (21) Appl. No.: 11/611,936 (22) Filed: Dec. 18, 2006 Related U.S. Application Data and their pharmaceutically acceptable salts, tautomers or in vivo-hydrolysable precursors, compositions and methods of (60) Provisional application No. 60/752,137, filed on Dec. use thereof. These novel compounds provide a treatment or 20, 2005. Provisional application No. 60/823,693, prophylaxis of anxiety disorders, cognitive disorders, and/or filed on Aug. 28, 2006. mood disorders. US 2007/0142328A1 Jun. 21, 2007 COMPOUNDS AND USES THEREOF are pentameric, ligand-gated chloride ion (Cl) channels 0001. The present application claims the benefit of U.S. belonging to a Superfamily of ligand-gated ionotropic recep Provisional Applications 60/752,137, filed Dec.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • WO 2015/072853 Al 21 May 2015 (21.05.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/072853 Al 21 May 2015 (21.05.2015) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 45/06 (2006.01) A61K 31/5513 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/045 (2006.01) A61K 31/5517 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/522 (2006.01) A61P 31/22 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A61K 31/551 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, PCT/NL20 14/050781 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (22) International Filing Date: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 13 November 2014 (13.1 1.2014) SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 61/903,433 13 November 2013 (13.
    [Show full text]
  • The Organic Chemistry of Drug Synthesis
    The Organic Chemistry of Drug Synthesis VOLUME 2 DANIEL LEDNICER Mead Johnson and Company Evansville, Indiana LESTER A. MITSCHER The University of Kansas School of Pharmacy Department of Medicinal Chemistry Lawrence, Kansas A WILEY-INTERSCIENCE PUBLICATION JOHN WILEY AND SONS, New York • Chichester • Brisbane • Toronto Copyright © 1980 by John Wiley & Sons, Inc. All rights reserved. Published simultaneously in Canada. Reproduction or translation of any part of this work beyond that permitted by Sections 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc. Library of Congress Cataloging in Publication Data: Lednicer, Daniel, 1929- The organic chemistry of drug synthesis. "A Wiley-lnterscience publication." 1. Chemistry, Medical and pharmaceutical. 2. Drugs. 3. Chemistry, Organic. I. Mitscher, Lester A., joint author. II. Title. RS421 .L423 615M 91 76-28387 ISBN 0-471-04392-3 Printed in the United States of America 10 987654321 It is our pleasure again to dedicate a book to our helpmeets: Beryle and Betty. "Has it ever occurred to you that medicinal chemists are just like compulsive gamblers: the next compound will be the real winner." R. L. Clark at the 16th National Medicinal Chemistry Symposium, June, 1978. vii Preface The reception accorded "Organic Chemistry of Drug Synthesis11 seems to us to indicate widespread interest in the organic chemistry involved in the search for new pharmaceutical agents. We are only too aware of the fact that the book deals with a limited segment of the field; the earlier volume cannot be considered either comprehensive or completely up to date.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,283,192 B2 Mullen Et Al
    US009283192B2 (12) United States Patent (10) Patent No.: US 9,283,192 B2 Mullen et al. (45) Date of Patent: Mar. 15, 2016 (54) DELAYED PROLONGED DRUG DELIVERY 2009. O1553.58 A1 6/2009 Diaz et al. 2009,02976O1 A1 12/2009 Vergnault et al. 2010.0040557 A1 2/2010 Keet al. (75) Inventors: Alexander Mullen, Glasgow (GB); 2013, OO17262 A1 1/2013 Mullen et al. Howard Stevens, Glasgow (GB); Sarah 2013/0022676 A1 1/2013 Mullen et al. Eccleston, Scotstoun (GB) FOREIGN PATENT DOCUMENTS (73) Assignee: UNIVERSITY OF STRATHCLYDE, Glasgow (GB) EP O 546593 A1 6, 1993 EP 1064937 1, 2001 EP 1607 O92 A1 12/2005 (*) Notice: Subject to any disclaimer, the term of this EP 2098 250 A1 9, 2009 patent is extended or adjusted under 35 JP HO5-194188 A 8, 1993 U.S.C. 154(b) by 0 days. JP 2001-515854. A 9, 2001 JP 2001-322927 A 11, 2001 JP 2003-503340 A 1, 2003 (21) Appl. No.: 131582,926 JP 2004-300148 A 10, 2004 JP 2005-508326 A 3, 2005 (22) PCT Filed: Mar. 4, 2011 JP 2005-508327 A 3, 2005 JP 2005-508328 A 3, 2005 (86). PCT No.: PCT/GB2O11AOOO3O7 JP 2005-510477 A 4/2005 JP 2008-517970 A 5, 2008 JP 2009-514989 4/2009 S371 (c)(1), WO WO99,12524 A1 3, 1999 (2), (4) Date: Oct. 2, 2012 WO WOO1 OO181 A2 1, 2001 WO WOO3,O266.15 A2 4/2003 (87) PCT Pub. No.: WO2011/107750 WO WOO3,O26625 A1 4/2003 WO WO 03/026626 A2 4/2003 PCT Pub.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,026,285 B2 Bezwada (45) Date of Patent: Sep
    US008O26285B2 (12) United States Patent (10) Patent No.: US 8,026,285 B2 BeZWada (45) Date of Patent: Sep. 27, 2011 (54) CONTROL RELEASE OF BIOLOGICALLY 6,955,827 B2 10/2005 Barabolak ACTIVE COMPOUNDS FROM 2002/0028229 A1 3/2002 Lezdey 2002fO169275 A1 11/2002 Matsuda MULT-ARMED OLGOMERS 2003/O158598 A1 8, 2003 Ashton et al. 2003/0216307 A1 11/2003 Kohn (75) Inventor: Rao S. Bezwada, Hillsborough, NJ (US) 2003/0232091 A1 12/2003 Shefer 2004/0096476 A1 5, 2004 Uhrich (73) Assignee: Bezwada Biomedical, LLC, 2004/01 17007 A1 6/2004 Whitbourne 2004/O185250 A1 9, 2004 John Hillsborough, NJ (US) 2005/0048121 A1 3, 2005 East 2005/OO74493 A1 4/2005 Mehta (*) Notice: Subject to any disclaimer, the term of this 2005/OO953OO A1 5/2005 Wynn patent is extended or adjusted under 35 2005, 0112171 A1 5/2005 Tang U.S.C. 154(b) by 423 days. 2005/O152958 A1 7/2005 Cordes 2005/0238689 A1 10/2005 Carpenter 2006, OO13851 A1 1/2006 Giroux (21) Appl. No.: 12/203,761 2006/0091034 A1 5, 2006 Scalzo 2006/0172983 A1 8, 2006 Bezwada (22) Filed: Sep. 3, 2008 2006,0188547 A1 8, 2006 Bezwada 2007,025 1831 A1 11/2007 Kaczur (65) Prior Publication Data FOREIGN PATENT DOCUMENTS US 2009/0076174 A1 Mar. 19, 2009 EP OO99.177 1, 1984 EP 146.0089 9, 2004 Related U.S. Application Data WO WO9638528 12/1996 WO WO 2004/008101 1, 2004 (60) Provisional application No. 60/969,787, filed on Sep. WO WO 2006/052790 5, 2006 4, 2007.
    [Show full text]
  • 1 441 702 B1
    (19) TZZ__Z _T (11) EP 1 441 702 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 31/4045 (2006.01) A61P 25/20 (2006.01) 10.05.2017 Bulletin 2017/19 A61K 9/20 (2006.01) (21) Application number: 02760523.7 (86) International application number: PCT/IL2002/000662 (22) Date of filing: 12.08.2002 (87) International publication number: WO 2003/015690 (27.02.2003 Gazette 2003/09) (54) METHOD FOR TREATING PRIMARY INSOMNIA VERFAHREN ZUR BEHANDLUNG PRIMÄRER INSOMNIA METHODE DE TRAITEMENT DE L’INSOMNIE PRIMAIRE (84) Designated Contracting States: • ROTH T ET AL: "Consensus for the AT BE BG CH CY CZ DE DK EE ES FI FR GB GR pharmacological management of insomnia in th IE IT LI LU MC NL PT SE SK TR enew millennium", INTERNATIONAL JOURNAL Designated Extension States: OF CLINICAL PRACTICE, MEDICON LT LV RO SI INTERNATIONAL, ESHER, GB, vol. 55, no. 1, 1 January 2001 (2001-01-01), page 10PAGES, (30) Priority: 14.08.2001 IL 14490001 XP002990688, ISSN: 1368-5031 • PERLIS M L ET AL: "Psychophysiological (43) Date of publication of application: insomnia: the behavioural model and a 04.08.2004 Bulletin 2004/32 neurocognitive perspective", JOURNAL OF SLEEP RESEARCH, BLACKWELL SCIENTIFIC, (60) Divisional application: OXFORD, GB, vol. 6, 1 January 1997 (1997-01-01), 16172415.8 / 3 103 443 pages 179-188, XP002990686, ISSN: 0962-1105, DOI: DOI:10.1046/J.1365-2869.1997.00045.X (73) Proprietor: NEURIM PHARMACEUTICALS (1991) • SILVA J A C E ET AL: "Special report from a LIMITED symposium held by the WHO and the World Tel Aviv 69710 (IL) Federation of sleep research societies: an overview of insomnias and related disorders - (72) Inventor: ZISAPEL, Nava recognition, epidemiology and rational 69355 Tel Aviv (IL) management", SLEEP, ALLEN PRESS, LAWRENCE, KS,US, vol.
    [Show full text]
  • The Organic Chemistry of Drug Synthesis
    THE ORGANIC CHEMISTRY OF DRUG SYNTHESIS VOLUME 3 DANIEL LEDNICER Analytical Bio-Chemistry Laboratories, Inc. Columbia, Missouri LESTER A. MITSCHER The University of Kansas School of Pharmacy Department of Medicinal Chemistry Lawrence, Kansas A WILEY-INTERSCIENCE PUBLICATION JOHN WILEY AND SONS New York • Chlchester • Brisbane * Toronto • Singapore Copyright © 1984 by John Wiley & Sons, Inc. All rights reserved. Published simultaneously in Canada. Reproduction or translation of any part of this work beyond that permitted by Section 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc. Library of Congress Cataloging In Publication Data: (Revised for volume 3) Lednicer, Daniel, 1929- The organic chemistry of drug synthesis. "A Wiley-lnterscience publication." Includes bibliographical references and index. 1. Chemistry, Pharmaceutical. 2. Drugs. 3. Chemistry, Organic—Synthesis. I. Mitscher, Lester A., joint author. II. Title. [DNLM 1. Chemistry, Organic. 2. Chemistry, Pharmaceutical. 3. Drugs—Chemical synthesis. QV 744 L473o 1977] RS403.L38 615M9 76-28387 ISBN 0-471-09250-9 (v. 3) Printed in the United States of America 10 907654321 With great pleasure we dedicate this book, too, to our wives, Beryle and Betty. The great tragedy of Science is the slaying of a beautiful hypothesis by an ugly fact. Thomas H. Huxley, "Biogenesis and Abiogenisis" Preface Ihe first volume in this series represented the launching of a trial balloon on the part of the authors. In the first place, wo were not entirely convinced that contemporary medicinal (hemistry could in fact be organized coherently on the basis of organic chemistry.
    [Show full text]